Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Volumn 15, Issue 1, 1988, Pages 15-19

  Bass, B ^a   Weinshenker, B ^a   Rice, G P A ^a   Noseworthy, J H ^a   Cameron, M G P ^a   Hader, W ^a   Bouchard, S ^a   Ebers, G C ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; CYCLOBENZAPRINE; DANTROLENE; DIAZEPAM; ORPHENADRINE; TIZANIDINE;

ADVERSE DRUG REACTION; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; ORAL DRUG ADMINISTRATION; SOMNOLENCE; SPASTICITY;

ADULT; AGED; BACLOFEN; BRAIN; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; MALE; MIDDLE AGE; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; SUPPORT, NON-U.S. GOV'T;

EID: 0023848956     PISSN: 03171671     EISSN: 20570155     Source Type: Journal    
DOI: 10.1017/S0317167100027104     Document Type: Article

References (12)

1. Young RR and Delwaide PJ. Drug therapy - spasticity. Engl J Med 1981; 304: 28–33.28-33; 96–99.
2. Sachais BA, Logue JN and Carey MS. Baclofen, a new antispastic drug. Arch Neurol 1977; 34: 422–428. 327987
3. Coward DM. Selective muscle relaxant properties of tizanidine and an examination of its mode of action. Triangle 1981; 20: 151–158.
4. Ringwald E, Campian SJ, Gerstenbrand F, Klinische erfahrungen mit einem neuartigen myotonolytikum (DS 103-282 Sandoz). Nervenarzt 1977; 48: 355–358. 333301
5. Rinne UK. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res 1980; 28: 827–836.
6. Poser CM, Paty DW, Scheinberg L, New diagnostic criteria for multiple sclerosis; guidelines for research protocols. Ann Neurol 1983; 13: 227–231. 6847134
7. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–52. 6685237
8. Siegel S. Non parametric statistics for behavioral sciences. New York: McGraw Hill, 1956.
9. Pederson E.A. rating system for neurological impairment in multiple sclerosis. Acta Neurol Scand 1965; 41; (suppl 13): 557–8. 5867096
10. Hassan N, and Mclellan DL. Double blind comparison of single doses of DS-103-282, baclofen and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 1980; 43: 1132–1136. 7217960
11. Smolenski C, Muff S, Smolenski-Kautz S. A double blind comparative trial of a new muscle relaxant, tizanidine and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981; 7: 374–383. 7016449
12. Delwaide PJ. Electrophysiological analysis of the mode of action of muscle relaxants in spasticity. Ann Neurol 1985; 17: 90–95. 3985591